About LEAD Horizon

Who is LEAD Horizon?

We are an Austrian company founded in early 2020 by Assoc.- Prof. Dr. med. Christoph Steininger and Michael Putz. Together with business partners we developed the innovative and patent pending self-test set for the detection of COVID-19. Our goal is to counteract the spread of the corona virus and to set an example for Austria and the world.

LEAD Horizon offers COVID-19 tests for the following target groups:

• private persons
• Companies
• Associations
• Culture/sport facilities
• Care facilities
• Educational institutions
• and much more.

Combination of science and economy

LEAD Horizon fuses science and business in one: With Prof. Dr. med. Christoph Steininger, we have one of the most renowned virologists in Austria on our team. Michael Putz has 16 years of experience in business consulting and an extensive network of business partners. Putz is the commercial law director of LEAD Horizon.

Our strengths:

• We offer solutions for small to large organizations and protect against business interruption.
• The test set we have developed can be easily applied by people of all ages.
• A network of partner laboratories makes it possible to quickly evaluate a large number of tests.
• Using a specially developed software solution via WeApp, we deliver the test results within 24 hours of receipt of the sample in a simple and understandable way.
• We work closely with our all-encompassing partner network of industrial companies and scientific partners.

About Assoc.- Prof. Dr. med. Christoph Steininger: 

Christoph Steininger is a virologist, infectiologist and internist at the Medical University of Vienna. After studying human medicine in Innsbruck, he worked at the Medical University of Vienna, University Medical Center Hamburg-Eppendorf (Germany), Cayetano Heredia University Lima (Peru), and University of California, San Diego (USA). Prof. Steininger is head of the research group "Viral Infections" and the Institute for Microbiome Research of the Karl-Landsteiner Society.

"Safety, quality, reliability - the drive-in stations close decisive gaps in sample collection and logistics for the detection of SARS-Cov-2".

Publications: 

1. Bilgilier, C. et al., 2017. Prospective, multicenter clinical study on inter- and intra-patient genetic variability for antimicrobial resistance of Helicobacter pylori. Clinical Microbiology and Infection. Available at: http://dx.doi.org/10.1016/j.cmi.2017.06.025.
2. Thannesberger, J. et al., 2017. Viruses comprise an extensive pool of mobile genetic elements in eukaryote cell cultures and human clinical samples. The FASEB Journal, 31(5), pp.1987-2000. Available at: http://dx.doi.org/10.1096/fj.201601168r.
3. Steininger, C., 2012. Cytomegalovirus vaccine: light on the horizon. The Lancet Infectious Diseases, 12(4), pp.257-259. Available at: http://dx.doi.org/10.1016/S1473-3099(11)70367-X.
4. Steininger, C. et al., 2012. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood, 119(10), pp.2293-2301. Available at: http://dx.doi.org/10.1182/blood-2011-08-374058.
5. Kump, P. et al., 2014. Empfehlungen zur Anwendung der fakalen Mikrobiotatransplantation �Stuhltransplantation�: Konsensus der Osterreichischen Gesellschaft für Gastroenterologie und Hepatologie (OGGH) in Zusammenarbeit mit der Osterreichischen Gesellschaft für Infektiologie und Tropenmedizin (OEGIT). Zeitschrift für Gastroenterologie, 52(12), pp.1485-1492. Available at: http://dx.doi.org/10.1055/s-0034-1385562.